Pacific Biosciences/$PACB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Ticker

$PACB
Sector
Primary listing

Employees

575

PACB Metrics

BasicAdvanced
$448M
-
-$1.83
2.17
-

What the Analysts think about PACB

Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.

Bulls say / Bears say

PacBio reported stronger-than-expected preliminary Q1 2025 revenue of $36.9 million, beating expectations and demonstrating resilient demand for its sequencing consumables amidst funding headwinds. (Reuters)
The company’s cost-cutting measures, including eliminating approximately 120 positions to reduce annual adjusted operating expenses by $45 – $50 million while maintaining its full-year revenue forecast of $155 – $170 million, underscore disciplined financial management and preserve cash runway. (Reuters)
China’s ban on importing Illumina sequencers opens a significant market opportunity for PacBio to capture displaced demand in Greater China, a region accounting for roughly 7% of Illumina’s sales, potentially boosting PacBio’s instrument placements and consumables revenue. (Reuters)
Preliminary Q1 2025 revenue for PacBio fell 5% year-over-year to $36.9 million, highlighting its vulnerability to academic funding constraints and fluctuating instrument sales cycles. (Reuters)
The announced layoffs of approximately 120 positions reflect underlying financial strain and risk diminishing PacBio’s R&D and sales capabilities critical for future product development. (Reuters)
NIH’s policy to cap indirect cost reimbursement rates at 15%—down from around 27%—threatens to slash as much as $4 billion annually from research funding, intensifying cash flow pressure on academic and clinical customers that drive roughly one-fifth of PacBio’s revenue. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

PACB Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PACB Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PACB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs